Pharmaceutical Commerce
OCTOBER 24, 2024
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, forecasts how cyber threats could potentially evolve over the next decade.
Bio Pharma Dive
OCTOBER 24, 2024
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its commercial outlook.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
OCTOBER 24, 2024
Biopharmaceutical solutions organization Syneos Health has announced the appointment of Costa Panagos as its new Chief Executive Officer (CEO). Panagos, an industry veteran with extensive experience in the healthcare and life sciences sector, takes over from Colin Shannon, who served as CEO for one year following the company’s acquisition by a consortium of private equity firms.
Pharmaceutical Technology
OCTOBER 24, 2024
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
OCTOBER 24, 2024
The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell has opted to end development of two current pipeline programs.
Pharmaceutical Technology
OCTOBER 24, 2024
Nitrosamines are organic compounds that have gained attention in the pharma industry as impurities in manufacturing.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
OCTOBER 24, 2024
The generic drug industry faces significant regulatory challenges that can impact the quality and safety of these life-saving medications. With the majority of generic drugs manufactured overseas, ensuring compliance with regulatory standards is crucial. This article delves into the complexities of generic drug regulation, highlighting the challenges faced by the U.S.
Bio Pharma Dive
OCTOBER 24, 2024
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
Pharmaceutical Technology
OCTOBER 24, 2024
In pharma, smaller-scale AI and supervised machine learning models could provide more effective solutions than large language models (LLM).
Bio Pharma Dive
OCTOBER 24, 2024
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple shots on the market and in development.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
OCTOBER 24, 2024
danicopan shown to improve haemoglobin levels and reduce anaemia
Bio Pharma Dive
OCTOBER 24, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
Pharmaceutical Technology
OCTOBER 24, 2024
The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage.
Velocity Clinical Research
OCTOBER 24, 2024
As of today, VISION technology has now contributed to over 7,000 randomizations across the U.S. and Europe. At just a year since its launch, VISION is already making clinical trials more accessible to all on a global scale. We’re proud of the impact our team and technology are making in advancing clinical research. Here’s to the next 7,000 and beyond!
Pharmaceutical Technology
OCTOBER 24, 2024
The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
pharmaphorum
OCTOBER 24, 2024
UK scheme to tackle "historically low" numbers of people taking part in dementia trials launches with £20m in government funding
Pharmaceutical Technology
OCTOBER 24, 2024
At CPHI Europe, an expert discussed the significance of implementing effective AI strategies to improve nutraceutical products.
pharmaphorum
OCTOBER 24, 2024
WhatsApp message earns Moderna a reprimand under the ABPI Code, with Novo Nordisk, Otsuka, AstraZeneca and Daiichi Sankyo also breaching the rules
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
OCTOBER 24, 2024
Chronic myeloid leukaemia – CML – is difficult to monitor and manage using traditional solutions. New RNA-based assays are helping.
pharmaphorum
OCTOBER 24, 2024
Legal win leads Amgen to at-risk launch of Eylea biosimilar Phil.
Pharmaceutical Technology
OCTOBER 24, 2024
The opioid addiction treatment market will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.
pharmaphorum
OCTOBER 24, 2024
Hyntelo offers cutting-edge AI solutions like GenAI for enhanced customer engagement. Learn how Hyntelo integrates as a Veeva AI Partner.
Pharmaceutical Technology
OCTOBER 24, 2024
MSD has acquired cancer therapeutics developer Modifi Biosciences, enhancing its portfolio with preclinical compounds.
pharmaphorum
OCTOBER 24, 2024
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.
Pharmaceutical Technology
OCTOBER 24, 2024
Double Point Ventures (DPV) has entered a definitive merger agreement to acquire all outstanding shares of Lumos for $38m.
pharmaphorum
OCTOBER 24, 2024
Explore the future of drug development by integrating open source and commercial software. Learn how this innovative approach is revolutionising the field of drug discovery.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
OCTOBER 24, 2024
TreeFrog has entered a research collaboration with the University of Pittsburgh to investigate the role of TLS in immuno-oncology.
pharmaphorum
OCTOBER 24, 2024
Gilead Sciences has achieved success with its HIV treatment drugs, including tenofovir disoproxil fumarate, but faces criticism for pricing and access issues. Learn about the controversy and efforts to expand access to these life-saving medications.
Pharmaceutical Technology
OCTOBER 24, 2024
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
Drug Channels
OCTOBER 24, 2024
Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
64 
Let's personalize your content